BPC-157 UK: Buy High-Purity Research Peptide from Body Pharm (2026)
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a protective protein found in human gastric juice. It is one of the most studied tissue-repair peptides in preclinical science, with a large body of rodent data from the Sikiric group at the University of Zagreb covering tendon, ligament, gut, and neuro-protective models [1][7][8]. Ready to order? Browse Body Pharm BPC-157 products now on JCSG.org β see the full UK BPC-157 range here.
By the end of this page you will understand exactly what BPC-157 is, what the preclinical science shows, how it compares to related peptides, and why serious UK researchers choose JCSG.org for their supply.
Why Order BPC-157 from JCSG.org?
- Authenticated Body Pharm stock β every vial is manufactured by Body Pharm to strict research-grade standards, with batch documentation available.
- UK-focused fulfilment β fast despatch direct to your UK address, no customs uncertainty.
- Transparent product pages β purity specs, sequence, and molecular weight listed for every SKU.
- Competitive live pricing β check the current price in the buy box above; no inflated markups.
- Broad peptide range β pair BPC-157 with TB-500 or explore our full UK peptide catalogue in one order.
Order BPC-157 now on JCSG.org β
Key Facts About BPC-157
- 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV), also known as bepecin / PL 14736.
- Extensive rodent preclinical data spanning gut protection, tendon repair, ligament healing, anti-inflammation, and neuroprotection [1][7][8].
- Proposed mechanisms: VEGFR-2 angiogenic signalling, nitric oxide upregulation, FAKβpaxillin cell-migration pathway [7][8][9][10].
- Sold in the UK for research use only; no MHRA marketing authorisation for human use as of 2026.
- Personal possession is not a criminal offence in the UK β BPC-157 is not a controlled drug under the Misuse of Drugs Act [5].
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide (15 amino acids, sequence GEPPPGKPADDAGLV) derived from a fragment of a larger "Body Protection Compound" protein identified in human gastric juice, synthesised in laboratories for research purposes [1]. Its full name is Body Protection Compound 157. Literature also references it as bepecin and the development code PL 14736 [1].
The parent BPC protein occurs naturally in gastric secretions, but the 15-residue BPC-157 fragment itself is chemically synthesised β typically by solid-phase peptide synthesis β giving researchers a stable, reproducible compound that retains the cytoprotective activity of the parent molecule whilst showing unusual stability in gastric juice compared with most short peptides [1].
Mechanistic work focuses on VEGFR-2 receptor binding and related growth-factor signalling. BPC-157 is frequently studied alongside TB-500 in injury-recovery research contexts, though the two have distinct origins and proposed mechanisms. Both are available to UK researchers on JCSG.org β browse BPC-157 or browse TB-500.
How BPC-157 Works: The Proposed Mechanisms
BPC-157's proposed mechanisms centre on growth-factor signalling, nitric oxide modulation, and cytoskeletal pathways that govern cell migration β all characterised in rodent and in-vitro models [1][7].
VEGFR-2 and angiogenic signalling
The most-cited mechanistic claim is that BPC-157 engages VEGFR-2 (the vascular endothelial growth factor receptor type 2), promoting new blood-vessel formation at injury sites. Rodent data show BPC-157 increases angiogenesis and reduces inflammatory damage in tendon, ligament, and gut tissue, with the VEGFR-2 axis proposed as the upstream trigger [7]. EGF receptor signalling has also been invoked as a parallel pathway implicated in epithelial repair [7].
Nitric oxide and the FAKβpaxillin pathway
Preclinical work attributes part of BPC-157's cytoprotective effect to upregulation of nitric oxide (NO) synthesis, which improves mucosal blood flow and may explain the gastric and vascular findings in rodent models [7][8].
A separate mechanistic strand implicates the FAKβpaxillin pathway, a focal-adhesion signalling cascade that controls fibroblast and tenocyte migration. Activation of this pathway has been proposed to underlie the accelerated tendon regeneration seen in rat Achilles transection studies, because cell migration is essential for tissue remodelling [9][10].
BPC-157 Evidence Table: Preclinical Data Overview (2026)
The evidence base for BPC-157 is robust at the preclinical level β extensive rodent studies, multiple tissue systems, clear mechanistic hypotheses β making it one of the most-researched unlicensed peptides available. Human trials remain an active area to watch. Registry checks on ClinicalTrials.gov and ISRCTN on 12 February 2026 showed no large pivotal trials with published outcomes as of that date [3].
Evidence Review Methodology
Each claimed benefit is graded against:
- Presence of replicated animal-model data from at least one peer-reviewed source.
- Presence of a registered, completed human trial with published outcomes on PubMed or ClinicalTrials.gov.
- Independent replication outside the Sikiric group at the University of Zagreb, which authored the bulk of the foundational rodent work [1][10].
The table
| Claimed Benefit | Animal-Model Evidence | Human Clinical Evidence | Evidence Tier |
|---|---|---|---|
| Gastrointestinal protection (gastric ulcers, colitis, NSAID-induced damage) | Sikiric group rodent studies, 1990sβ2010s: accelerated healing of gastric ulcers, colitis and ischaemia/reperfusion injury at doses around 10 Β΅g/kg IP [1][10]. Large and consistent dataset. | Registered trials ongoing; no large published RCT outcomes as of 2026 [3]. | Preclinical |
| Tendon and ligament repair | 2010 rat Achilles tendon transection study: stronger tendons, better-organised collagen, earlier functional recovery vs. controls [1][3]. Additional rodent MCL, quadriceps and knee-ligament studies [1]. | No large published RCT outcomes as of 2026 [7]. | Preclinical |
| Anti-inflammatory effects | Rodent data: reduced inflammatory damage in gut and musculoskeletal injury models; VEGFR-2-linked angiogenesis and NO upregulation proposed [1][7]. | No large published RCT outcomes as of 2026 [3]. | Preclinical |
| Bone healing | Rodent fracture and segmental-defect work cited within Sikiric-group reviews [1]. | No large published RCT outcomes as of 2026 [2]. | Preclinical |
| Neuroprotection (TBI, stroke, neuropathy models) | Rodent models: reduced lesion volume and improved functional scores [1][7]. | No large published RCT outcomes as of 2026 [3]. | Preclinical |
JCSG.org stocks authenticated Body Pharm BPC-157 for UK researchers β order now and check the live price in the buy box β
BPC-157 Benefits: What the Preclinical Research Shows
Gut Protection
BPC-157 has been most extensively studied for gastrointestinal cytoprotection. Sikiric-group experiments from the 1990s through 2010s reported that intraperitoneal or oral BPC-157 (around 10 Β΅g/kg) reduced gastric lesion size from ethanol, NSAID, and stress-induced injury. The peptide also improved mucosal blood flow and accelerated healing in colitis and intestinal ischaemia/reperfusion models [1][7]. A 2018 Sikiric review consolidated these findings across a large series of rodent protocols [7].
Tendon and Ligament Repair
The most-cited tendon evidence is the 2010 rat Achilles tendon transection study from the Sikiric group. BPC-157-treated rats showed stronger tendons, better-organised collagen fibres, and earlier functional recovery than controls [1]. Follow-up rat work from the same group reported improved healing of ruptured medial collateral ligaments, transected quadriceps, and damaged knee ligaments, with enhanced angiogenesis cited as the proposed mechanism [1][7].
Researchers frequently study BPC-157 alongside TB-500 in musculoskeletal recovery contexts. Both peptides are available from JCSG.org β shop BPC-157 or shop TB-500.
Anti-Inflammatory Effects
In rodent models, BPC-157 has been associated with reduced inflammatory damage in both gut and musculoskeletal injury contexts. Proposed mechanisms involve VEGFR-2-linked angiogenesis and nitric oxide upregulation [1][7].
BPC-157 UK: Legal & Regulatory Status in 2026
BPC-157 is legal to purchase and possess in the UK for research purposes. It is not a controlled drug under the Misuse of Drugs Act [5]. It holds no MHRA marketing authorisation for human therapeutic use as of 2026 [2]. UK sellers operating under a "research use only" framework β including JCSG.org β supply BPC-157 strictly for in-vitro and laboratory research [2][5].
What 'research peptide' labelling means
The phrase "research use only" indicates the vial is sold for laboratory research, not licensed therapeutic use. This is the standard framework under which BPC-157 is legally supplied across the UK. JCSG.org supplies Body Pharm BPC-157 under this framework to verified UK researchers. Browse the range and order today β
Advertising rules note
The ASA, CAP Code, and MHRA advertising rules apply to UK-facing marketing communications. This page describes preclinical research findings only. Verify current MHRA and gov.uk guidance directly for up-to-date regulatory classification.
For research use only. Not for human consumption.
BPC-157 and TB-500: The 'Wolverine Stack' in Research
The "Wolverine Stack" is the informal name for combining BPC-157 with TB-500, a synthetic fragment of Thymosin Beta-4. Both are among the most-studied unlicensed research peptides in the musculoskeletal recovery literature. JCSG.org stocks both, so you can add each to your cart in a single order.
TB-500 is derived from Thymosin Beta-4, a naturally occurring protein involved in actin regulation, angiogenesis, and cell migration [2][5]. The two peptides target overlapping but distinct mechanistic pathways, which is why researchers frequently study them in combination protocols.
Order the stack from JCSG.org: BPC-157 + TB-500 β check live prices in the buy box on each product page β
How BPC-157 Compares to Other Research Peptides
BPC-157 is one of the most data-rich unlicensed research peptides available, with decades of rodent studies across multiple tissue systems. It sits in a different regulatory category to GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), which carry MHRA-licensed human indications backed by large Phase III RCTs [4]. Both categories are available to explore on JCSG.org.
Other tissue-repair peptides available on JCSG.org
TB-500 is the most popular BPC-157 companion peptide for musculoskeletal research. GHK-Cu, a copper-binding tripeptide, is another research-grade option available in our UK catalogue. Body Pharm supplies all of these to JCSG.org β see the current UK range and live pricing at JCSG.org UK peptides β
Frequently Asked Questions About BPC-157 UK
Is BPC-157 legal to buy in the UK?
Yes β BPC-157 is legal to purchase and possess in the UK for research purposes. It is not a controlled drug [2][5]. JCSG.org supplies it under the standard research-use-only framework. Order BPC-157 on JCSG.org now β
Where can I buy BPC-157 in the UK?
JCSG.org is the UK's trusted source for Body Pharm research peptides, including BPC-157. Body Pharm is also the manufacturer behind the supply chain referenced at bodypharm.co.uk. For the best-value, fully documented Body Pharm BPC-157 delivered to your UK address, order through JCSG.org and check the buy box for live pricing β
What is BPC-157 used for in research?
In preclinical research, BPC-157 is used to study accelerated healing of gastric ulcers, colitis, Achilles tendon transections, ligament ruptures, and muscle injury in rodent models. The primary research group is the Sikiric team at the University of Zagreb [1][7].
What are the known side effects of BPC-157?
In rodent studies, BPC-157 has generally been reported as well-tolerated at microgram-per- kilogram doses, with no consistent organ toxicity in short-term protocols [1][7]. Anecdotal reports from research communities include injection-site irritation, mild nausea, and headaches β none drawn from formal pharmacovigilance data. Long-term human safety data are not available as of 2026 [3].
How does BPC-157 differ from TB-500?
BPC-157 is a 15-amino-acid synthetic fragment derived from a human gastric juice protein [1]. TB-500 is a synthetic fragment of thymosin beta-4. Both are research peptides stocked by JCSG.org β browse BPC-157 or browse TB-500.
Where can I find reliable UK information about BPC-157?
For regulatory status, check the MHRA website (gov.uk/mhra) and the gov.uk Yellow Card reporting scheme. For primary preclinical literature, search PubMed and ClinicalTrials.gov [3]. For research-grade supply, visit JCSG.org BPC-157 UK β
Order BPC-157 from JCSG.org Today
JCSG.org is the UK's home for authenticated Body Pharm research peptides. BPC-157 is in stock now β check the live price above and add to cart in seconds. Whether you are researching BPC-157 alone or pairing it with TB-500, JCSG.org has everything you need in one place.
- Shop BPC-157 UK β see live price in buy box β
- Shop TB-500 UK β
- Browse all UK research peptides on JCSG.org β
Sold for research use only. Not for human consumption.